Results 1 to 10 of about 84,619 (287)

Heterologous vaccine interventions: boosting immunity against future pandemics [PDF]

open access: yesMolecular Medicine, 2021
While vaccines traditionally have been designed and used for protection against infection or disease caused by one specific pathogen, there are known off-target effects from vaccines that can impact infection from unrelated pathogens.
Daniela Marín-Hernández   +2 more
doaj   +3 more sources

Unsolved Puzzles Surrounding HCV Immunity: Heterologous Immunity Adds Another Dimension. [PDF]

open access: yesInt J Mol Sci, 2017
Chronic infection with hepatitis C virus (HCV) afflicts 3% of the world’s population and can lead to serious and late-stage liver diseases. Developing a vaccine for HCV is challenging because the correlates of protection are uncertain and traditional vaccine approaches do not work.
Agrawal B   +5 more
europepmc   +4 more sources

Heterologous immune responses in health and disease

open access: yesИнфекция и иммунитет, 2020
Immunological memory and tolerance represent major achievements and advantages of adaptive immunity. Organisms bearing adaptive immunity display prominent competitive advantages in the fight against infections.
A. P. Toptygina
doaj   +3 more sources

How to Employ Trained Immunity and Trained Immunity-Based Vaccines to Inhibit Allergic Inflammation [PDF]

open access: yesVaccines
Trained immunity confers protection against subsequent unrelated infections through metabolic and epigenetic reprogramming. Unlike adaptive immunity, trained innate immunity provides broad, non-specific protection against diverse heterologous pathogens ...
Wonho Kim, Dooil Jeoung
doaj   +2 more sources

Respiratory syncytial virus infection induces heterologous protection against SARS-CoV-2 through γδ T cell-mediated trained immunity and the activation of SARS-CoV-2–reactive mucosal T cells [PDF]

open access: yesJournal of Virology
Respiratory viruses can infect hosts concurrently or sequentially, potentially influencing each other’s pathogenic trajectory. However, the underlying immune mechanisms governing these interactions remain poorly understood.
Awadalkareem Adam   +7 more
doaj   +2 more sources

Cross reactive cellular immune responses in chickens previously exposed to low pathogenic avian influenza [PDF]

open access: yesBMC Proceedings, 2011
Background Avian influenza (AI) infection in poultry can result in high morbidity and mortality, and negatively affect international trade. Because most AI vaccines used for poultry are inactivated, our knowledge of immunity against AI is based largely ...
Kapczynski Darrell R   +5 more
doaj   +2 more sources

Broadening SARS-CoV-2 Immunity by Combining ORFV and Protein-Based Vaccines [PDF]

open access: yesVaccines
Background: Emerging immune-evasive viral variants threaten the efficacy of current vaccines, underscoring the need for strategies that elicit broad and durable protection.
Alena Reguzova   +4 more
doaj   +2 more sources

HETEROLOGOUS IMMUNITY STUDIES IN CALVES IN IRAN [PDF]

open access: yesIranian Journal of Public Health, 1976
In a series of heterologous immunity studies S. haematobium, S. bovis and O. turkestanicum in calves, a large number of S. haematobium cercariae (21,000 cercariae) were used repeatedly as the immunization agent.
J. Massoud
doaj   +3 more sources

The impact of interferon-γ pathway on trained immunity induction by vaccination with Bacille Calmette-Guérin [PDF]

open access: yesScientific Reports
Bacillus Calmette-Guérin (BCG) has multiple heterologous off-target effects which extend beyond tuberculosis (TB) prophylaxis, which include protection against other non-tuberculous infections, autoimmune diseases, and tumor development.
Ekaterina Isachesku   +9 more
doaj   +2 more sources

Heterologous Immunity Between SARS-CoV-2 and Pathogenic Bacteria

open access: yesFrontiers in Immunology, 2022
Heterologous immunity, when the memory T cell response elicited by one pathogen recognizes another pathogen, has been offered as a contributing factor for the high variability in coronavirus disease 2019 (COVID-19) severity outcomes.
Peter J. Eggenhuizen   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy